Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Laith Alzweri

Urology Galveston, TX Medical Doctor

NPI 1285173690 CMS profile 7654841

301 University Blvd., Utmb Health Urology- Galveston, Galveston, TX 77555

Open in the dashboard

General payments

$9,934

93 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laith Alzweri of Galveston, TX is reported in the CMS Open Payments database as having received $9,934 across 93 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,263 13
2024 General $760 11
2023 General $4,897 29
2022 General $1,272 20
2021 General $645 10
2020 General $1,096 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laith Alzweri
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Laith Alzweri were reported at $1,263. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Laith Alzweri Urology median Middle half National median
2019 $0 $480 $147–$1,201 $163
2020 $1,096 $246 $87–$645 $114
2021 $645 $358 $111–$1,000 $132
2022 $1,272 $476 $143–$1,263 $149
2023 $4,897 $560 $168–$1,461 $160
2024 $760 $563 $170–$1,464 $164
2025 $1,263 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Coloplast Corp $5,603 53 payments
  2. Boston Scientific Corporation $3,389 19 payments
  3. Endo Pharmaceuticals Inc. $405 13 payments
  4. Endo USA, Inc. $146 1 payment
  5. Myriad Genetic Laboratories, Inc. $124 1 payment
  6. Antares Pharma, Inc. $100 2 payments
  7. HealthTronics Mobile Solutions, LLC $57 1 payment
  8. Medtronic, Inc. $47 1 payment
  9. AstraZeneca Pharmaceuticals LP $35 1 payment
  10. ABC Home Medical Supply, Inc. $28 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $5,215 74 payments
  2. Travel and Lodging $4,684 18 payments
  3. Education $35 1 payment
Products named General payments · program years 2020–2025
  1. Titan Men's Health $4,385 40 payments
  2. Moses 550 D\F\L $1,519 5 payments
  3. TITAN Penile Reconstruction $803 4 payments
  4. XIAFLEX $551 14 payments
  5. AVEED $255 12 payments
  6. Porges Coloplast $207 2 payments
  7. EDEX $160 8 payments
  8. Moses $141 1 payment
  9. PENILE & TESTICULAR RECONSTRUCTN $139 2 payments
  10. PROLARIS $124 1 payment
  11. Other $624 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

746

Median for Urology: 1,053

Drug cost

$23,338

Median for Urology: $101,464

Branded share of claims

21%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 24 $11,607
Testosterone Generic 18 $4,292
Tamsulosin Hcl Generic 259 $3,216
Testosterone Cypionate Generic 43 $1,089
Trospium Chloride Generic 36 $977
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 51 $662
Cephalexin Generic 128 $509
Oxybutynin Chloride Generic 55 $322
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 43 $266
Finasteride Generic 16 $109

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$72,466

Medicare's payments for the services billed

Medicare patients

267

Average age 74

Services billed

739

22 women, 245 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 40%
Ischemic heart disease 37%
Chronic kidney disease 30%
Heart failure 24%
Cancer 24%
Atrial fibrillation 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

93 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record